The Amylin Pharmaceuticals, Inc. Puzzle and Tracking Bydureon Sales

As pundits continue to ponder the unanswered questions surrounding Amylin Pharmaceuticals and its rejection of a bid by Bristol-Myers Squibb – did the big drugmaker really make a bid? if so, when? and why did Amylin say no? – a key issue has been the value of the Bydureon diabetes drug.

A great deal rides on Bydureon, of course, because this is the franchise drug for Amylin, which is locked in a race with Novo Nordisk to dominate the market for the GLP-1 class of diabetes medications. Novo Nordisk sells Victoza. But there has been debate about the extent to which Bydureon, which was approved earlier this year by the FDA, can truly succeed..

Back to news